Letrozole


Non-steroidal aromatase inhibitor (third generation)

A potent non-steroidal aromatase inhibitor; superior to anastrozole at suppressing plasma estradiol and used in postmenopausal breast cancer and ovulation induction.

Abstract

Letrozole (4,4′-(1H-1,2,4-triazol-1-ylmethylene)bis(benzonitrile); CAS 112809-51-5; molecular formula C17H11N5; molecular weight 285.31) is a non-steroidal third-generation aromatase inhibitor developed at Novartis and approved by the FDA in 1997 under the trade name Femara. The greater potency translates to slightly superior progression-free survival in head-to-head trials versus anastrozole in metastatic breast cancer, with similar tolerability. Plasma half-life is approximately 42 hours; metabolism is hepatic via CYP2A6 and CYP3A4. Approved indications include adjuvant and metastatic ER-positive postmenopausal breast cancer; off-label use in PCOS-related anovulatory infertility (often more effective than clomiphene per the PPCOS II trial) and as estrogen control in androgen-using populations. Used as the most potent reference aromatase inhibitor.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph